Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus low-dose radioactive iodine ablation in intermediate-risk differentiated thyroid cancer
IRCT2016011626038N1Phase 2Completed
- Sponsor
- Nuclear Medicine Research Center
- Start
- Dec 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of iodine-131 in thyroid cancer and well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Nuclear Medicine Research Center. Started Dec 2014; status: completed.
02
Drugs
iodine-131
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on IRCT2016011626038N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016011626038N1.